Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.5, with a high ...

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment ...

Chad Robins, CEO & Co-Founder, emphasized "another quarter of strong execution and accelerating momentum across the business," highlighting meaningful wins in profitability and growth for the MRD ...

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment of ...

Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers ...

Adaptive shares are trading higher on possible continued momentum after the company announced preliminary fourth-quarter and ...

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) surged around 16% in premarket trading on Monday after the company reported preliminary fourth-quarter revenue that came in well ahead of ...

GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Taylor Soper on Jan 6, 2026 at 8:51 ...

The MarketWatch News Department was not involved in the creation of this content. A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data ...

Adaptive Biotechnologies reported a 42% revenue increase in its MRD segment, with a focus on achieving profitability in 2025. Adaptive Biotechnologies Corporation reported its financial results for ...

SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...

Adaptive Biotechnologies Corporation and Flatiron Health have announced the integration of Adaptive's clonoSEQ® test for measurable residual disease (MRD) assessment into Flatiron's OncoEMR® ...